Literature DB >> 22231607

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

Annie L Culver1, Ira S Ockene, Raji Balasubramanian, Barbara C Olendzki, Deidre M Sepavich, Jean Wactawski-Wende, Joann E Manson, Yongxia Qiao, Simin Liu, Philip A Merriam, Catherine Rahilly-Tierny, Fridtjof Thomas, Jeffrey S Berger, Judith K Ockene, J David Curb, Yunsheng Ma.   

Abstract

BACKGROUND: This study investigates whether the incidence of new-onset diabetes mellitus (DM) is associated with statin use among postmenopausal women participating in the Women's Health Initiative (WHI).
METHODS: The WHI recruited 161,808 postmenopausal women aged 50 to 79 years at 40 clinical centers across the United States from 1993 to 1998 with ongoing follow-up. The current analysis includes data through 2005. Statin use was captured at enrollment and year 3. Incident DM status was determined annually from enrollment. Cox proportional hazards models were used to estimate the risk of DM by statin use, with adjustments for propensity score and other potential confounding factors. Subgroup analyses by race/ethnicity, obesity status, and age group were conducted to uncover effect modification.
RESULTS: This investigation included 153,840 women without DM and no missing data at baseline. At baseline, 7.04% reported taking statin medication. There were 10,242 incident cases of self-reported DM over 1,004,466 person-years of follow-up. Statin use at baseline was associated with an increased risk of DM (hazard ratio [HR], 1.71; 95% CI, 1.61-1.83). This association remained after adjusting for other potential confounders (multivariate-adjusted HR, 1.48; 95% CI, 1.38-1.59) and was observed for all types of statin medications. Subset analyses evaluating the association of self-reported DM with longitudinal measures of statin use in 125,575 women confirmed these findings.
CONCLUSIONS: Statin medication use in postmenopausal women is associated with an increased risk for DM. This may be a medication class effect. Further study by statin type and dose may reveal varying risk levels for new-onset DM in this population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231607     DOI: 10.1001/archinternmed.2011.625

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  119 in total

1.  Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate.

Authors:  Vassilios G Athyros; Dimitri P Mikhailidis
Journal:  Nat Rev Endocrinol       Date:  2012-02-07       Impact factor: 43.330

2.  Dietary Manganese, Plasma Markers of Inflammation, and the Development of Type 2 Diabetes in Postmenopausal Women: Findings From the Women's Health Initiative.

Authors:  Jung Ho Gong; Kenneth Lo; Qing Liu; Jie Li; Shuiqing Lai; Aladdin H Shadyab; Chrisa Arcan; Linda Snetselaar; Simin Liu
Journal:  Diabetes Care       Date:  2020-04-15       Impact factor: 19.112

3.  Resveratrol potentiates effect of simvastatin on inhibition of mevalonate pathway in human endometrial stromal cells.

Authors:  Jesus A Villanueva; Anna Sokalska; Amanda B Cress; Israel Ortega; Kaylon L Bruner-Tran; Kevin G Osteen; Antoni J Duleba
Journal:  J Clin Endocrinol Metab       Date:  2013-02-05       Impact factor: 5.958

Review 4.  Problems and possible solutions for therapy with statins.

Authors:  Thomas F Whayne
Journal:  Int J Angiol       Date:  2013-06

Review 5.  Statins for Primary Prevention in Older Adults-Moving Toward Evidence-Based Decision-Making.

Authors:  Sonal Singh; Susan Zieman; Alan S Go; Stephen P Fortmann; Nanette K Wenger; Jerome L Fleg; Barbara Radziszewska; Neil J Stone; Sophia Zoungas; Jerry H Gurwitz
Journal:  J Am Geriatr Soc       Date:  2018-10-02       Impact factor: 5.562

6.  All-cause, cardiovascular, and cancer mortality rates in postmenopausal white, black, Hispanic, and Asian women with and without diabetes in the United States: the Women's Health Initiative, 1993-2009.

Authors:  Yunsheng Ma; James R Hébert; Raji Balasubramanian; Nicole M Wedick; Barbara V Howard; Milagros C Rosal; Simin Liu; Chloe E Bird; Barbara C Olendzki; Judith K Ockene; Jean Wactawski-Wende; Lawrence S Phillips; Michael J Lamonte; Kristin L Schneider; Lorena Garcia; Ira S Ockene; Philip A Merriam; Deidre M Sepavich; Rachel H Mackey; Karen C Johnson; Joann E Manson
Journal:  Am J Epidemiol       Date:  2013-09-17       Impact factor: 4.897

Review 7.  Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk.

Authors:  Morton Leibowitz; Chandra Cohen-Stavi; Sanjay Basu; Ran D Balicer
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

8.  Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults.

Authors:  Ishak Mansi; Christopher R Frei; Chen-Pin Wang; Eric M Mortensen
Journal:  J Gen Intern Med       Date:  2015-04-28       Impact factor: 5.128

9.  Quantifying the effect of statin use in pre-diabetic phenotypes discovered through association rule mining.

Authors:  John R Schrom; Pedro J Caraballo; M Regina Castro; György J Simon
Journal:  AMIA Annu Symp Proc       Date:  2013-11-16

10.  Statins and risk of treated incident diabetes in a primary care population.

Authors:  Nur Lisa Zaharan; David Williams; Kathleen Bennett
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.